Today: 3 February 2026
Subscribe
Browse Category

NYSE:TRI News 14 December 2025 - 24 December 2025

Gold Price UK Surges to Around £3,330/oz as Bullion Breaks $4,500 on 24 December 2025

Gold Price UK Surges to Around £3,330/oz as Bullion Breaks $4,500 on 24 December 2025

London, Wednesday 24 December 2025 — Gold prices are finishing the year with a decisive “Santa rally” in the UK, driven by a global record-breaking surge that has pushed the metal above $4,500 per ounce for the first time and lifted UK spot levels to roughly the £3,320–£3,330 per troy ounce range.  Investing.com In early trading on Christmas Eve, spot gold hit a record $4,525.19 before…
24 December 2025
·····
Gold Price in UAE Today (15 December 2025): Dubai 24K Hits Dh523.75/Gram as Global Bullion Climbs to a Seven-Week High

Gold Price in UAE Today (15 December 2025): Dubai 24K Hits Dh523.75/Gram as Global Bullion Climbs to a Seven-Week High

Dubai, UAE — 15 December 2025: Gold prices in the UAE moved higher on Monday, with Dubai’s benchmark retail rates pushing to fresh December highs as international bullion climbed on a softer US dollar and easing Treasury yields. The day’s action has kept both jewellery buyers and investors on alert, especially with key US jobs data in focus and major banks…
15 December 2025
···
Ripple Valuation Today (Dec. 14, 2025): Why Ripple Labs Is Being Priced Around $40 Billion—and What Could Move It Next

Ripple Valuation Today (Dec. 14, 2025): Why Ripple Labs Is Being Priced Around $40 Billion—and What Could Move It Next

Updated: December 14, 2025 Ripple Labs’ valuation has become one of the most closely watched numbers in crypto-fintech—partly because Ripple is still private, and partly because 2025 has turned into a turning point for regulated stablecoins, institutional custody, and bank-style charters. As of today (14/12/2025), the clearest, most widely reported benchmark for Ripple’s company valuation remains about $40 billion, anchored…
14 December 2025
····

Stock Market Today

  • ACADIA Pharmaceuticals Seen as Undervalued Despite Recent Rebound, DCF Model Shows
    February 2, 2026, 10:21 PM EST. ACADIA Pharmaceuticals (NASDAQ: ACAD) shares trade around $26, showing a mixed return profile: roughly flat year-to-date, up 41.2% over the past year, yet down 49% versus five years ago. The stock currently trades at a price-to-earnings (P/E) ratio of 16.9x, below the biotech industry average of 20.3x, signaling market caution. However, a discounted cash flow (DCF) model using a two-stage free cash flow to equity approach estimates ACADIA's intrinsic value at $140.47 per share, suggesting an 81.4% undervaluation. The model factors in projected free cash flow growth from $142.7 million over the past 12 months to an estimated $780 million by 2030. These projections highlight potential long-term value despite near-term volatility. Investors should weigh these valuations against sector risks and company fundamentals before making decisions.
Go toTop